FDA gives Long Grove OK for generic Halaven

Long Grove Pharmaceuticals has received the Food and Drug Administration’s blessing for eribulin mesylate injection, which is the generic of the chemotherapy medication Halaven.

“Our goal is to create more affordable pathways to pharmaceuticals. The introduction of a generic in a market where choices are limited is an important step to ensure patient access,” said Peter Karas, chief commercial officer of Long Grove Pharmaceuticals. “We’re grateful for the opportunity to ensure that more patients benefit from this cancer treatment.”

[Read more: Long Grove gets FDA OK for generic Radicava]

Eribulin mesylate injection is a cancer medication that disrupts the growth of cancer cells. It was originally approved by the FDA in November 2010 to treat adult patients with locally advanced or metastatic breast cancer whose treatment has not progressed well through other cancer medicines. The FDA expanded its approval in January 2016 to adult patients who have already received anthracycline-containing therapy for advanced or metastatic liposarcoma.

[Read more: Long Grove gets FDA OK for generic Radicava]